| An SI Board Since November 2015 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 0 |
0 |
0
|
$GILD |
|
Gilead Sciences, Inc. incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
GILD's profit margin has been consistent or even increasing over the past three years (Current year: 48.62%, Last year: 27.45%, Two years ago: 26.71%), passing the requirement. It is a sign of good management and a healthy and competitive enterprise
Companies with sales less than $500 million should be chosen. It is among these small-cap stocks that investors can find "an uncut gem", ones that institutions won't be able to buy yet. GILD's sales of $29,194.1 million based on trailing 12 month sales, are too high and would therefore fail the test. It is companies with $500 million or less in sales that are most likely to double or triple in size in the next few years.
GILD's income tax paid expressed as a percentage of pretax income either this year (18.83%) or last year (27.35%) is below 20% which is cause for concern. Because the tax rate is below 20% this could mean that the earnings that were reported are unrealistically inflated due to the lower level of income tax paid. However, we have utilized a sophisticated formula so that the appropriate figures reflect a 'normal' tax rate (35%).
Anyone following this stock?
|
|
|
